Albany Molecular Research SVP Unloads $42,325 in Stock (AMRI)
Albany Molecular Research (NASDAQ:AMRI) SVP Steven R. Hagen sold 2,500 shares of Albany Molecular Research stock in a transaction dated Tuesday, June 3rd. The stock was sold at an average price of $16.93, for a total value of $42,325.00. Following the transaction, the senior vice president now directly owns 31,730 shares in the company, valued at approximately $537,189. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.
Albany Molecular Research (NASDAQ:AMRI) traded down 0.70% during mid-day trading on Friday, hitting $17.12. The stock had a trading volume of 21,100 shares. Albany Molecular Research has a 52-week low of $9.71 and a 52-week high of $20.55. The stock has a 50-day moving average of $15.99 and a 200-day moving average of $13.92. The company has a market cap of $538.6 million and a price-to-earnings ratio of 56.90.
Albany Molecular Research (NASDAQ:AMRI) last posted its quarterly earnings results on Tuesday, May 6th. The company reported $0.16 EPS for the quarter, missing the Thomson Reuters consensus estimate of $0.23 by $0.07. The company had revenue of $51.00 million for the quarter, compared to the consensus estimate of $62.19 million. Analysts expect that Albany Molecular Research will post $0.82 EPS for the current fiscal year.
Several analysts have recently commented on the stock. Analysts at TheStreet upgraded shares of Albany Molecular Research from a “hold” rating to a “buy” rating in a research note on Wednesday. Finally, analysts at Zacks downgraded shares of Albany Molecular Research from an “outperform” rating to a “neutral” rating in a research note on Tuesday, April 15th. They now have a $17.80 price target on the stock.
Albany Molecular Research, Inc (NASDAQ:AMRI) is a contract research and manufacturing company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.